As
filed with the Securities and Exchange Commission on December 12, 2023
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
S-8
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
ADIAL
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
82-3074668 |
(State
or other jurisdiction of
incorporation or organization) |
|
(I.R.S.
Employer No.)
Identification
Number) |
1180
Seminole Trail, Suite 495
Charlottesville, Virginia 22901
(434) 422-9800
(Address,
including ZIP code, and telephone number, including area code, of registrant’s principal executive office)
ADIAL
PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN
(Full
title of the Plan)
Cary
J. Claiborne
President
and Chief Executive Officer
Adial
Pharmaceuticals, Inc.
1180 Seminole Trail, Suite 495
Charlottesville, Virginia 22901
(434) 422-9800
(Name,
address and telephone number of agent for service)
with
copies to:
Leslie
Marlow, Esq.
Patrick
J. Egan, Esq.
Hank
Gracin, Esq
Blank
Rome LLP
1271
Avenue of the Americas
New
York, New York 10020
(212)
885-5000
(Name,
address and telephone number)
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated
filer ☐ |
Accelerated
filer ☐ |
Non-accelerated filer ☒ |
Smaller reporting company
☒ |
|
Emerging growth company
☒ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANATORY
NOTE
Adial
Pharmaceuticals, Inc. (the “Registrant” or the “Company”) filed with the Securities and Exchange Commission (the
“Commission”) its Registration Statement on Form S-8 (Registration No. 333-226884) on August 16, 2018 (the “2018 Registration
Statement”) for the purpose of registering under the Securities Act of 1933, as amended (the “Securities Act”), 1,750,000
shares (70,000 shares post-Reverse Stock Split (as defined below)) of common stock, par value $0.001 per share (the “Common Stock”),
to be offered and sold under the Registrant’s 2017 Equity Incentive Plan (hereinafter referred to as the “Plan”). Pursuant
to General Instruction E to Form S-8, the contents of the 2018 Registration Statement are incorporated into this Registration Statement
by reference.
The
Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-233760) on September 13, 2019
(the “2019 Registration Statement”) pursuant to and in accordance with the requirements of General Instruction E to Form
S-8 for the purpose of registering under the Securities Act an additional 1,750,000 shares (70,000
shares post-Reverse Stock Split) of Common Stock to be offered and sold under the Plan. These
additional shares of Common Stock were added pursuant to the adoption of Amendment No. 1 to the Plan. Pursuant to General Instruction
E to Form S-8, the contents of the 2019 Registration Statement are incorporated into this Registration Statement by reference.
The
Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-248759) on September 11, 2020
(the “2020 Registration Statement”) pursuant to and in accordance with the requirements of General Instruction E to Form
S-8 for the purpose of registering under the Securities Act an additional 2,000,000 shares (80,000
shares post-Reverse Stock Split) of Common Stock to be offered and sold under the Plan. These
additional shares of Common Stock were added pursuant to the adoption of Amendment No. 2 to the Plan. Pursuant to General Instruction
E to Form S-8, the contents of the 2020 Registration Statement are incorporated into this Registration Statement by reference.
The
Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-260304) on October 15, 2021 (the
“2021 Registration Statement”) to register an additional 2,000,000 shares (80,000 shares post-Reverse Stock Split)
of Common Stock that were added to the Plan by a vote of the Registrant’s stockholders at the Registrant’s 2021 Annual
Meeting of Stockholders, which was held on September 27, 2021. These additional shares of Common
Stock were added pursuant to the adoption of Amendment No. 3 to the Plan. The aggregate number of shares of Common Stock issuable under
the Plan, as amended, after the adoption of Amendment No. 3 to the Plan, was 7,500,000 shares (300,000 shares post-Reverse Stock
Split). Pursuant to General Instruction E to Form S-8, the contents of the 2021 Registration
Statement are incorporated into this Registration Statement by reference.
The
Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-267972) on October 21, 2022 (the
“2022 Registration Statement”) to register an additional 2,000,000 shares (80,000 shares post-Reverse Stock Split)
of Common Stock that were added to the Plan by a vote of the Registrant’s stockholders at the Registrant’s 2022 Annual
Meeting of Stockholders, which was held on October 13, 2022. These additional shares of Common
Stock were added pursuant to the adoption of Amendment No. 4 to the Plan. The aggregate number of shares of Common Stock issuable under
the Plan, as amended, after the adoption of Amendment No. 4 to the Plan, was 9,500,000 shares (380,000 shares post-Reverse Stock
Split). Pursuant to General Instruction E to Form S-8, the contents of the 2022 Registration
Statement are incorporated into this Registration Statement by reference.
On
August 4, 2023, the Registrant effected a reverse stock split of its outstanding shares of Common Stock at a ratio of 1-for-25 (the “Reverse
Stock Split”), which reduced the number of shares of Common Stock reserved under the Plan to 380,000. The Registrant is filing
this Registration Statement on Form S-8 (the “Registration Statement”) to register an additional 120,000 shares of Common
Stock that were added to the Plan by a vote of the Registrant’s Board of Directors and the Registrant’s stockholders at the
Registrant’s 2023 Annual Meeting of Stockholders, which was held on November 2, 2023. These
additional 120,000 shares of Common Stock were added pursuant to the adoption of Amendment No. 5 to the Plan. The aggregate number of
shares of Common Stock that may be issued under the Plan, as amended, after the adoption of Amendment No. 5 to the Plan, is 500,000 shares.
PART
I
INFORMATION
REQUIRED IN THE SECTION 10(a) PROSPECTUS
The
information specified in Item 1 and Item 2 of Part I of this Registration Statement on Form S-8 is omitted from this filing in accordance
with the provisions of Rule 428 under the Securities Act, and the introductory note to Part I of Form S-8. The documents containing the
information specified in Part I will be delivered to the participants in the Plan as required by Rule 428(b)(1). Such documents and the
documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken
together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
PART
II
INFORMATION
REQUIRED IN THE REGISTRATION STATEMENT
Item
3. Incorporation of Documents by Reference.
The
Securities and Exchange Commission (the “Commission”) allows the Registrant to “incorporate by reference” the
information it files with it which means that it can disclose important information to you by referring you to those documents instead
of having to repeat the information in this prospectus. The information incorporated by reference is considered to be part of this prospectus,
and later information that the Registrant files with the Commission will automatically update and supersede this information. The Registrant
incorporates by reference the documents listed below and any future filings made with the Commission (Commission File
No. 001-38323) under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus and the termination
of the offering:
|
● |
the
Registrant’s Annual Report on Form 10-K for
the fiscal year ended December 31, 2022 (the “Annual Report”) filed with the Commission on March 30, 2023, as
updated in the Registrant’s Current Report on Form 8-K filed with the Commission on September 27, 2023 solely to recast
certain financial information and related disclosures included in such Annual Report; |
|
● |
the
Registrant’s Quarterly Report on Form 10-Q
for the quarter ended March 31, 2023 filed with the Commission on May 12, 2023, the
Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 filed with the Commission on August 21, 2023,
as amended by the Quarterly Report on Form 10-Q/A for the quarter ended June 30, 2023 filed with the Commission on October 30, 2023,
and the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the Commission on November
14, 2023; |
|
● |
the
Registrant’s Current Reports on Form 8-K filed
with the Commission on February 1, 2023 (other than as indicated therein), February 21, 2023 (other than as indicated therein), February 24, 2023, February 27, 2023, March 2, 2023, March 7, 2023
(other than as indicated therein), March 21, 2023 (other than as indicated therein), April 13, 2023, May 10, 2023 (other than as indicated therein), May 24, 2023, June 2, 2023, July 10, 2023, August 4, 2023, August 23, 2023, September 21, 2023, September 27, 2023, October 24, 2023, November 6, 2023, November 14, 2023, November 28, 2023, and November 29, 2023; |
|
● |
the
Registrant’s Definitive Proxy Statement on Schedule
14A filed with the Commission on October 2, 2023 and the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on December 8, 2023; and |
|
● |
the
description of the Registrant’s common stock set forth in (i) the Registrant’s registration statement on Form
8-A12B, filed with the Commission on December 11, 2017, as amended by the registration
statement on Form
8-A12B/A filed with the Commission on July 23, 2018, and (ii) Exhibit
4.17—Description of Securities to the Registrant’s Annual Report on Form
10-K for the fiscal year ended December 31, 2022 filed with the Commission on March 30, 2023. |
All
reports and other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act
shall be deemed to be incorporated by reference in this Registration Statement and to be a part of this Registration Statement from the
respective date of filing of each of those reports or documents until the filing of a post-effective amendment to this Registration Statement
which indicates either that all securities offered by this Registration Statement have been sold or which deregisters all of the securities
under this Registration Statement then remaining unsold.
Any
statement contained in this Registration Statement or in a document incorporated or deemed to be incorporated by reference in this Registration
Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained
in this Registration Statement or in any other subsequently filed document which also is or is deemed to be incorporated by reference
in this Registration Statement modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except
as so modified or superseded, to constitute a part of this Registration Statement.
Item
4. Description of Securities.
The
class of securities to be offered is registered under Section 12 of the Exchange Act.
Item 5.
Interests of Named Experts and Counsel.
Not
applicable.
Item 6.
Indemnification of Directors and Officers.
The
Registrant is incorporated under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law provides that
a Delaware corporation may indemnify any persons who were, are, or are threatened to be made, parties to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such
corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation, or is or
was serving at the request of such corporation as an officer, director, employee or agent of another corporation or enterprise. The indemnity
may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner he or
she reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or
proceeding, had no reasonable cause to believe that his or her conduct was illegal except that no indemnification is permitted without
judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful
on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses
(including attorneys’ fees) actually and reasonably incurred.
The
Registrant’s certificate of incorporation and bylaws provide for the indemnification of its directors and officers to the fullest
extent permitted under the Delaware General Corporation Law.
Section
102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director
of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary
duties as a director, except for liability for any:
|
● |
transaction from which
the director derives an improper personal benefit; |
|
● |
act or omission not in
good faith or that involves intentional misconduct or a knowing violation of law; |
|
● |
unlawful payment of dividends
or redemption of shares; or |
|
● |
breach of a director’s
duty of loyalty to the corporation or its stockholders. |
The
Registrant’s certificate of incorporation includes such a provision. Expenses incurred by any officer or director in defending
any such action, suit or proceeding in advance of its final disposition shall be paid by the Registrant upon delivery to it of an undertaking,
by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director
or officer is not entitled to be indemnified by the Registrant.
Section
174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of an
unlawful payment of dividends or an unlawful stock purchase or redemption, may be held liable for such actions. A director who was either
absent when the unlawful actions were approved or dissented at the time may avoid liability by causing his or her dissent to such
actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately
after such absent director receives notice of the unlawful acts.
As
permitted by the Delaware General Corporation Law, the Registrant has entered into indemnity agreements with each of its directors and
executive officers, that require the Registrant to indemnify such persons against any and all costs and expenses (including attorneys’,
witness or other professional fees) actually and reasonably incurred by such persons in connection with any action, suit or proceeding
(including derivative actions), whether actual or threatened, to which any such person may be made a party by reason of the fact that
such person is or was a director or officer or is or was acting or serving as an officer, director, employee or agent of the Registrant
or any of its affiliated enterprises. Under these agreements, the Registrant is not required to provide indemnification for certain matters,
including:
|
● |
indemnification beyond
that permitted by the Delaware General Corporation Law; |
|
● |
indemnification for any
proceeding with respect to the unlawful payment of remuneration to the director or officer; |
|
● |
indemnification for certain
proceedings involving a final judgment that the director or officer is required to disgorge profits from the purchase or sale of
the Registrant’s stock; |
|
● |
indemnification for proceedings
involving a final judgment that the director’s or officer’s conduct was in bad faith, knowingly fraudulent or deliberately
dishonest or constituted willful misconduct or a breach of his or her duty of loyalty, but only to the extent of such specific determination; |
|
● |
indemnification for proceedings
or claims brought by an officer or director against us or any of the Registrant’s directors, officers, employees or agents,
except for claims to establish a right of indemnification or proceedings or claims approved by the Registrant’s board of directors
or required by law; |
|
● |
indemnification for settlements
the director or officer enters into without the Registrant’s consent; or |
|
● |
indemnification in violation
of any undertaking required by the Securities Act or in any registration statement filed by the Registrant. |
The
indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification thereunder.
The
Registrant has an insurance policy in place that covers its officers and directors with respect to certain liabilities, including liabilities
arising under the Securities Act or otherwise.
Item
7. Exemption from Registration Claimed.
Not
applicable.
Item
8. Exhibits.
EXHIBIT
INDEX
Exhibit
No. |
|
Description |
3.1 |
|
Certificate of Incorporation of Adial Pharmaceuticals, Inc. (1) |
3.2 |
|
Certificate of Amendment to Certificate of Incorporation of Adial Pharmaceuticals, Inc. (2) |
3.3 |
|
Amended and Restated Bylaws of Adial Pharmaceuticals,
Inc. (3) |
4.1 |
|
Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock
Plan, as amended (4) |
4.2 |
|
Amendment No. 1 to the
Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (5) |
4.3 |
|
Form of Stock Option Grant Notice, Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) and Notice of Exercise under the 2017 Equity Incentive Plan (6) |
4.4 |
|
Amendment No. 2 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (7) |
4.5 |
|
Amendment No. 3 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (8) |
4.6 |
|
Amendment No. 4 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (9) |
4.7 |
|
Amendment No. 5 to the Adial Pharmaceuticals, Inc. 2017 Equity Incentive Stock Plan (10) |
5.1 |
|
Opinion of Blank Rome LLP (11) |
23.1 |
|
Consent of Marcum, LLP, Independent Registered Public Accounting Firm (11) |
23.2 |
|
Consent of Blank Rome LLP (contained in Exhibit 5.1) (11) |
24.1 |
|
Power of Attorney (included on the signature page of this registration statement) (11) |
107 |
|
Filing Fee Table (11) |
(1) |
Incorporated
by reference to the Registrant’s Form S-1, as amended (File No. 333-220368), filed with the Securities and Exchange Commission
on October 25, 2017. |
(2) |
Incorporated by reference
to the Registrant’s Form 8-K (File No. 001-38323) filed with the Securities and Exchange Commission on August 4, 2023. |
(3) |
Incorporated by reference
to the Registrant’s Annual Report on Form 10-K (File No. 001-38323) filed with
the Securities and Exchange Commission March 28, 2022. |
(4) |
Incorporated by reference
to the Registrant’s Form S-8 (File No. 333-226884) filed with the Securities and Exchange Commission on August 16, 2018. |
(5) |
Incorporated by reference
to the Registrant’s Form S-8 (File No. 333-233760) filed with the Securities and Exchange Commission September 13, 2019. |
(6) |
Incorporated by reference
to the Registrant’s Form S-1, as amended (File No. 333-220368), filed with the Securities and Exchange Commission on September
7, 2017. |
(7) |
Incorporated by reference
to the Registrant’s Form S-8 (File No. 333-248759) filed with the Securities and Exchange Commission September 11, 2020. |
(8) |
Incorporated by reference
to the Registrant’s Current Report on Form 8-K (File No. 001-38323) filed with
the Securities and Exchange Commission September 29, 2021. |
(9) |
Incorporated by reference
to the Registrant’s Current Report on Form 8-K (File No. 001-38323) filed with
the Securities and Exchange Commission October 13, 2022. |
(10) |
Incorporated by reference
to the Registrant’s Current Report on Form 8-K (File No. 001-38323) filed with
the Securities and Exchange Commission November 6, 2023. |
Item 9.
Undertakings.
(a)
The Registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act.
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration
Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration
Fee” table in the Registration Statement.
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or
any material change to such information in the registration statement.
Provided,
however, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13
or Section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the Registration Statement.
(2)
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(b)
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of
the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable,
each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated
by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(h)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that
a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Charlottesville, Virginia, on the 12th day of December, 2023.
|
ADIAL PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/
Cary J. Claiborne |
|
Name: |
Cary
J. Claiborne |
|
Title: |
President
and Chief Executive Officer |
POWER
OF ATTORNEY
Each
of the undersigned, whose signature appears below, hereby constitutes and appoints each of Cary J. Claiborne and Joseph Truluck, act
singly, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution for him and in his name,
place and stead, in any and all capacities, to sign any or all amendments to this Registration Statement, whether pre-effective or post-effective,
and to file the same with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorney-in-fact and agent, or his substitute full power and authority to do and perform each and every act and thing
necessary or appropriate to be done with respect to this Registration Statement or any amendments hereto in the premises, as fully to
all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent,
or his substitute or substitutes, or any of them, may lawfully do or cause to be done by virtue thereof.
Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the
capacities and on the date indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Cary J.
Claiborne |
|
President
and Chief Executive Officer and Member of the |
|
December 12, 2023 |
Cary J. Claiborne |
|
Board of Directors |
|
|
|
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Joseph
M. Truluck |
|
Chief Operating Officer
and Chief Financial Officer |
|
December 12, 2023 |
Joseph M. Truluck |
|
(Principal Financial and
Accounting Officer) |
|
|
|
|
|
|
|
/s/ J. Kermit
Anderson |
|
Member of the Board of Directors |
|
December 12, 2023 |
J. Kermit Anderson |
|
|
|
|
|
|
|
|
|
/s/ Roberson
H. Gilliland |
|
Member of the Board of Directors |
|
December 12, 2023 |
Robertson H. Gilliland |
|
|
|
|
|
|
|
|
|
/s/ Tony Goodman |
|
Member of the Board of Directors |
|
December 12, 2023 |
Tony Goodman |
|
|
|
|
/s/
James W. Newman |
|
Member of the Board of Directors |
|
December 12, 2023 |
James W. Newman, Jr. |
|
|
|
|
|
|
|
|
|
/s/ Kevin
Schuyler |
|
Chairman of the Board of
Directors |
|
December 12, 2023 |
Kevin Schuyler, CFA |
|
|
|
|
II-6
Exhibit
5.1
![](https://www.sec.gov/Archives/edgar/data/1513525/000121390023095120/ex5-1_001.jpg)
1271
Avenue of the Americas |New York, NY 10020
blankrome.com
December
12, 2023
The
Board of Directors
Adial
Pharmaceuticals, Inc.
1180 Seminole Trail, Suite 495
Charlottesville, Virginia 22901
|
Re: |
Adial Pharmaceuticals, Inc.—Registration Statement
on Form S-8 |
Ladies
and Gentlemen:
We
refer to the Registration Statement on Form S-8 (the “Registration Statement”) filed on the date hereof by Adial Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission with respect to the registration
of up to an aggregate of 120,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”),
issuable pursuant to the Company’s 2017 Equity Incentive Plan, as amended through the date hereof (the “2017 Equity Incentive
Plan”).
We
have examined originals or certified copies of such corporate records of the Company and other certificates and documents of officials
of the Company, public officials and others as we have deemed relevant or appropriate for purposes of this opinion letter. We have assumed
the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity to authentic original
documents of all copies submitted to us as conformed and certified or reproduced copies. We have also assumed that all of the shares
eligible for issuance under the Plan following the date hereof will be issued for not less than par value.
Based
upon, and subject to, the foregoing, it is our opinion that the 120,000 Shares, when sold and issued in accordance with the provisions
of the 2017 Equity Incentive Plan and the Registration Statement and the related prospectus, will be validly issued, fully paid and non-assessable.
The
opinions in this opinion letter are qualified in their entirety and subject to the following:
| 1. | We
express no opinion as to the laws of any jurisdiction other than the General Corporation
Law of the State of Delaware. |
| 2. | This
opinion is given as of the date hereof and is limited to the matters stated herein, and no
opinion is implied or may be inferred beyond the matters expressly stated. We assume herein
no obligation, and hereby disclaim any obligation, to make any inquiry after the date hereof
or to advise you of any future changes in the foregoing or of any facts or circumstances
that may hereafter come to our attention. |
We
consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not thereby admit that
we are within the category of persons whose consent is required under Section 7 of the Securities Act and the rules and regulations
promulgated thereunder.
|
Very truly yours, |
|
|
|
/s/ BLANK ROME |
|
BLANK ROME LLP |
Blank
Rome LLP | blankrome.com
Exhibit
23.1
CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We
consent to the incorporation by reference in this Registration Statement of Adial Pharmaceuticals, Inc. on Form S-8 of our report dated
September 26, 2023, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect
to our audits of the consolidated financial statements of Adial Pharmaceuticals, Inc. as of and for the years ended December 31, 2022
and 2021 appearing in the Current Report on Form 8-K of Adial Pharmaceuticals, Inc. filed with the Securities and Exchange Commission
on September 27, 2023.
/s/
Marcum LLP
Marcum
LLP
Marlton,
New Jersey
December
12, 2023
Exhibit
107
Calculation
of Filing Fee Tables
Form
S-8
(Form
Type)
Adial
Pharmaceuticals, Inc.
(Exact
Name of Registrant as Specified in its Charter)
Table1
– Newly Registered Securities
Security Type | |
Security
Class
Title | | |
Fee
Calculation
Rule | | |
Amount
Registered(1)(2) | | |
Proposed
Maximum
Offering Price per
Unit(3) | | |
Maximum Aggregate
Offering
Price | | |
Fee Rate | | |
Amount of
Registration
Fee | |
Equity | |
| Common stock, par value $0.001 per share | | |
| Rule 457(c) and Rule 457(h)(2) | | |
| 120,000 | (3) | |
$ | 2.1225 | | |
$ | 254,700 | | |
| $147.60 per $1,000,000 | | |
$ | 37.60 | |
Total Offering Amounts | |
| | | |
| | | |
| | | |
$ | 254,700 | | |
| $147.60 per $1,000,000 | | |
$ | 37.60 | |
Total Fee Offsets(4) | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| — | |
Net Fee Due | | |
| | | |
| | | |
| | | |
| | | |
| | | |
$ | 37.60 | |
(1) |
The
securities to be registered include options and other rights to acquire the common stock, par value $0.001
per share, of Adial Pharmaceuticals, Inc. (the “Registrant”) issuable pursuant to the Registrant’s
2017 Equity Incentive Plan, as amended (the “Plan”).
|
|
|
(2) |
Pursuant
to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also
covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or similar
transaction.
|
|
|
(3) |
Calculated
pursuant to Rule 457(c) and 457(h) of the Securities Act solely for purposes of calculating the registration
fee. The price for the 120,000 shares of common stock under the Plan is based upon the average of the high
and low sale prices of the Registrant’s common stock reported on the Nasdaq Capital Market on December
7, 2023.
|
|
|
(4) |
The Registrant
does not have any fee offsets to claim. |
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Aug 2023 to Aug 2024